(Q46767693)

25 December 2017

title

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis (English)

1 reference

25 December 2017

author name string

C Weder

1

1 reference

25 December 2017

G M Baltariu

2

1 reference

25 December 2017

K A Wyler

3

1 reference

25 December 2017

H-J Gober

4

1 reference

25 December 2017

C Lienert

5

1 reference

25 December 2017

M Schluep

6

1 reference

25 December 2017

E W Radü

7

1 reference

25 December 2017

G De Libero

8

1 reference

25 December 2017

L Kappos

9

1 reference

25 December 2017

P W Duda

10

1 reference

25 December 2017

publication date

1 November 2005

1 reference

25 December 2017

European Journal of Neurology

published in

1 reference

25 December 2017

volume

12

1 reference

25 December 2017

issue

11

1 reference

25 December 2017

page(s)

869-878

1 reference

25 December 2017

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

The Janus face of CNS-directed autoimmune response: a therapeutic challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Adhesion molecule expression and regulation on cells of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01084.X

10.1111/J.1468-1331.2005.01084.X

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017